Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | +1.50% | +15.34% | -86.21% |
11/04 | Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating | MT |
10/04 | Transcript : Amylyx Pharmaceuticals, Inc. - Special Call |
Chart calendar Amylyx Pharmaceuticals, Inc.
Upcoming events on Amylyx Pharmaceuticals, Inc.
Past events on Amylyx Pharmaceuticals, Inc.
16/04/2024 08:45 pm | American Academy of Neurology Meeting |
10/04/2024 11:00 pm | HELIOS Phase 2 Clinical Trial Results Call |
08/03/2024 06:30 pm | AMX0035 Phase III Clinical Trial Results Call |
05/03/2024 04:30 am | Muscular Dystrophy Association Clinical & Scientific Conference |
22/02/2024 06:30 pm | Q4 2023 Earnings Call |
22/02/2024 05:30 pm | Q4 2023 Earnings Release |
07/12/2023 11:15 pm | Motor Neurone Disease Association International Symposium - Poster No: TST-12 |
07/12/2023 10:15 pm | Motor Neurone Disease Association International Symposium - Poster No: CLT-11 |
07/12/2023 10:15 pm | Motor Neurone Disease Association International Symposium - Poster No: CW-06 |
06/12/2023 10:15 pm | Motor Neurone Disease Association International Symposium - Poster No: BIO-14 |
06/12/2023 10:15 pm | Motor Neurone Disease Association International Symposium - Poster No: CLT-10 |
06/12/2023 10:15 pm | Motor Neurone Disease Association International Symposium - Poster No: CLT-30 |
29/11/2023 12:40 am | Evercore ISI HealthCONx Conference |
09/11/2023 06:30 pm | Q3 2023 Earnings Call |
09/11/2023 05:30 pm | Q3 2023 Earnings Release |
19/10/2023 09:30 pm | Neuro PSP and CBD International Research Symposium |
06/10/2023 02:00 am | Northeast ALS Consortium Meeting - Poster Number: 125 |
06/10/2023 02:00 am | Northeast ALS Consortium Meeting - Poster Number: 124 |
06/10/2023 02:00 am | Northeast ALS Consortium Meeting - Poster Number: 123 |
06/10/2023 02:00 am | Northeast ALS Consortium Meeting - Poster Number: 90 |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,29 0,40 -28.08% | 22,2 4,41 403.57% | 381 380 0.27% | 102 |
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 -86,7 - | -201 -212 5.05% | 39,9 53,1 -24.81% | -129 |
EBIT Million USD | Released Forecast Spread | 0,00 | -82,7 -97,2 14.95% | -201 -212 4.84% | 38,8 52,9 -26.65% | -152 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -87,9 -92,0 4.42% | 0,00 0,00 - | 54,3 69,4 -21.78% | -178 |
Net income Million USD | Released Forecast Spread | -42,3 | -87,9 -97,2 9.5% | -198 -207 4.16% | 49,3 63,0 -21.78% | -105 |
EPS USD | Released Forecast Spread | -6,96 | -13,4 -15,4 13.03% | -3,39 -3,54 4.15% | 0,70 0,90 -22.38% | -1,54 |
Announcement Date | 26/04/21 | 30/03/22 | 13/03/23 | 22/02/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,25 - | 0,00 0,06 - | 0,00 0,08 - | 0,35 0,08 314.02% | 21,9 4,72 363.26% | 71,4 59,7 19.75% | 98,2 92,1 6.6% | 103 114 -9.65% | 108 107 1.31% | 98,3 | 7,68 | 0,05 | 0,05 |
EBIT Million USD | Released Forecast Spread | -52,3 -42,6 -22.6% | -47,8 -33,0 -44.72% | -54,3 -48,5 -11.89% | -54,7 -56,9 3.88% | -44,6 -53,4 16.47% | -2,05 -19,7 89.57% | 20,2 3,45 486.33% | 18,7 29,0 -35.46% | 1,93 14,6 -86.79% | -9,05 | -64,2 | -49,7 | -44,1 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -54,2 -37,0 -46.6% | -47,7 -50,0 4.6% | 1,40 -9,80 114.32% | 24,0 6,90 247.93% | 22,4 30,6 -26.76% | 6,48 21,6 -70.01% | -15,5 | -74,1 | -47,2 | -41,5 | |||
Net income Million USD | Released Forecast Spread | -54,2 -42,5 -27.63% | -47,8 -39,5 -21.03% | -54,1 -50,2 -7.78% | -53,8 -56,3 4.46% | -42,7 -51,3 16.78% | 1,57 -15,1 110.43% | 22,1 2,80 687.42% | 20,9 30,0 -30.33% | 4,73 16,5 -71.3% | 0,60 | -47,2 | -33,3 | -29,2 |
EPS USD | Released Forecast Spread | -4,15 -4,87 14.73% | -0,93 -0,75 -24.83% | -0,93 -0,92 -1.64% | -0,92 -0,97 4.66% | -0,65 -0,81 19.75% | 0,02 -0,22 109.09% | 0,31 -0,04 985.71% | 0,30 0,42 -29.13% | 0,07 0,23 -69.75% | 0,01 | -0,69 | -0,49 | -0,43 |
Announcement Date | 30/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 13/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 22/02/24 | - | - | - | - |
06/05/2024 04:30 pm | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
07/05/2024 | BIOTEST AG: Q1 2024 Earnings Release |
07/05/2024 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
07/05/2024 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
07/05/2024 11:30 am | BIOGAIA AB: Q1 2024 Earnings Release |
07/05/2024 05:00 pm | INTRA-CELLULAR THERAPIES, INC.: Q1 2024 Earnings Release |
08/05/2024 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
08/05/2024 | ZAI LAB LIMITED: Q1 2024 Earnings Release |
08/05/2024 05:25 pm | VERICEL CORPORATION: Q1 2024 Earnings Release |
09/05/2024 | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
Past sector events for Amylyx Pharmaceuticals, Inc.
03/05/2024 01:35 am | TWIST BIOSCIENCE CORPORATION: Q2 2024 Earnings Release |
02/05/2024 05:20 pm | ARBUTUS BIOPHARMA CORPORATION: Q1 2024 Earnings Release |
02/05/2024 05:00 pm | BRIDGEBIO PHARMA, INC.: Q1 2024 Earnings Release |
02/05/2024 | SK BIOSCIENCE CO.,LTD.: Q1 2024 Earnings Release |
30/04/2024 04:30 pm | INCYTE CORPORATION: Q1 2024 Earnings Release |
30/04/2024 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q4 2023 Earnings Release |
30/04/2024 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q1 2024 Earnings Release |
30/04/2024 | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED: Q4 2023 Earnings Release |
30/04/2024 03:23 am | SINOVAC BIOTECH LTD.: Q4 2023 Earnings Release |
29/04/2024 | SHANGHAI OPM BIOSCIENCES CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AMLX Stock
- Calendar Amylyx Pharmaceuticals, Inc.